# 2026年1月21日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. SGLT2 抑制剂对比 GLP-1 受体激动剂在 2 型糖尿病患者中的肾脏结局研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41557360)
**期刊：** JAMA internal medicine
**PMID：** 41557360
**DOI：** 10.1001/jamainternmed.2025.7409

### 第一部分 原文与翻译

**英文原标题：** SGLT2 Inhibitors vs GLP-1 Receptor Agonists for Kidney Outcomes in Individuals With Type 2 Diabetes.

> **英文摘要：**
> IMPORTANCE: No randomized clinical trial has directly compared the effectiveness of sodium-glucose cotransporter-2 inhibitor (SGLT2i) and glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment in reducing acute and chronic kidney outcomes. OBJECTIVE: To examine the comparative effectiveness of SGLT2i and GLP-1RA treatment for acute and chronic kidney outcomes in individuals with type 2 diabetes. DESIGN, SETTING, AND PARTICIPANTS: This comparative effectiveness study with a target trial emulation design used nationwide, population-based data from Denmark. Participants were individuals with metformin-treated type 2 diabetes who initiated SGLT2i or GLP-1RA treatment from January 2014 to November 2020, with follow-up through October 2024. EXPOSURE: Initiation of an SGLT2i or a GLP-1RA. MAIN OUTCOMES AND MEASURES: The 2 coprimary outcomes were chronic kidney disease (CKD; 40% reduction in estimated glomerular filtration rate [eGFR], severe albuminuria, or kidney failure) and acute kidney injury (AKI). Secondary outcomes included the individual components of CKD, albuminuria, and death. Intention-to-treat effects were estimated using inverse probability of treatment weights, comparing risks for CKD assessed by the Aalen-Johansen estimator, and AKI burden by mean cumulative counts (MCCs; mean number of events per individual as multiple AKI events were possible). Subgroup analyses included stratification by preexisting cardiovascular or kidney disease. RESULTS: The study included 36 279 individuals who initiated an SGLT2i and 18 782 who initiated a GLP-1RA (median [IQR] age, 63 [55-71] years vs 61 [52-70] years), with comparable diabetes duration, eGFR, and urine albumin-creatinine ratios. The weighted 5-year risk of CKD was 6.7% (95% CI, 6.4%-7.0%) for SGLT2i initiators and 8.2% (95% CI, 7.8%-8.6%) for GLP-1RA initiators (risk ratio: 0.81 [95% CI, 0.76-0.87]; risk difference: -1.5% [95% CI, -2.0% to -1.0%]). The 5-year MCC of AKI per 100 individuals was 25.2 (95% CI, 24.4-26.1) for SGLT2i initiators and 28.7 (95% CI, 27.4-30.0) for GLP-1RA initiators (MCC ratio: 0.88 [95% CI, 0.83-0.93]; MCC difference: -3.5 [95% CI, -5.0 to -2.0]). In contrast, the secondary outcomes of albuminuria and mortality were slightly reduced in GLP-1RA initiators. Results were consistent across subgroups, with the most pronounced CKD and AKI reductions with SGLT2i observed among individuals without preexisting kidney disease. CONCLUSIONS AND RELEVANCE: This comparative effectiveness study found that initiation of SGLT2i vs GLP-1RA treatment in individuals with type 2 diabetes was associated with a lower 5-year risk of CKD and a lower 5-year count of AKI. These findings underscore the potential of SGLT2i treatment for primary prevention of kidney disease in individuals with type 2 diabetes.

> **中文摘要：**
> 重要性：目前尚无随机临床试验直接比较钠-葡萄糖协同转运蛋白-2 抑制剂（SGLT2i）与胰高血糖素样肽-1 受体激动剂（GLP-1RA）治疗在减少急性及慢性肾脏结局方面的有效性。目的：旨在探讨 SGLT2i 与 GLP-1RA 治疗在 2 型糖尿病患者急性及慢性肾脏结局方面的比较有效性。设计、场所及参与者：这项采用目标试验模拟设计的比较有效性研究使用了来自丹麦的全源性人口数据。参与者为 2014 年 1 月至 2020 年 11 月期间启动 SGLT2i 或 GLP-1RA 治疗的二甲双胍治疗型 2 型糖尿病患者，随访至 2024 年 10 月。暴露：启动 SGLT2i 或 GLP-1RA 治疗。主要结局与测量指标：两个共同主要结局是慢性肾脏病（CKD；估算肾小球滤过率 [eGFR] 下降 40%、严重蛋白尿或肾衰竭）和急性肾损伤（AKI）。次要结局包括 CKD 的各组成部分、蛋白尿和死亡。使用逆概率治疗加权法估计意向性治疗效应，通过 Aalen-Johansen 估计器比较 CKD 风险，通过平均累积计数（MCCs；每个个体的平均事件数，因为可能发生多次 AKI 事件）评估 AKI 负担。亚组分析包括按预先存在的血管疾病或肾脏疾病进行分层。结果：研究纳入了 36,279 名启动 SGLT2i 治疗的个体和 18,782 名启动 GLP-1RA 治疗的个体（中位 [IQR] 年龄分别为 63 [55-71] 岁和 61 [52-70] 岁），两组在糖尿病病程、eGFR 和尿白蛋白-肌酐比值方面具有可比性。SGLT2i 启动者的加权 5 年 CKD 风险为 6.7% (95% CI, 6.4%-7.0%)，而 GLP-1RA 启动者为 8.2% (95% CI, 7.8%-8.6%)（风险比：0.81 [95% CI, 0.76-0.87]；风险差异：-1.5% [95% CI, -2.0% 至 -1.0%]）。SGLT2i 启动者的每 100 人 5 年 AKI 平均累积计数 (MCC) 为 25.2 (95% CI, 24.4-26.1)，而 GLP-1RA 启动者为 28.7 (95% CI, 27.4-30.0)（MCC 比：0.88 [95% CI, 0.83-0.93]；MCC 差异：-3.5 [95% CI, -5.0 至 -2.0]）。相比之下，GLP-1RA 启动者的蛋白尿和死亡率次要结局略有降低。各亚组结果一致，在无既往肾脏疾病的个体中观察到的 SGLT2i 对 CKD 和 AKI 的减少作用最为显著。结论与相关性：这项比较有效性研究发现，与 GLP-1RA 相比，在 2 型糖尿病患者中启动 SGLT2i 治疗与较低的 5 年 CKD 风险和较低的 5 年 AKI 发生数相关。这些发现强调了 SGLT2i 治疗在 2 型糖尿病患者肾脏疾病一级预防中的潜力。

### 第二部分 AI 大师评价

本研究通过目标试验模拟设计填补了 SGLT2i 与 GLP-1RA 在肾脏保护效应上直接对比的证据空白。在大规模真实世界人群中，研究证实 SGLT2i 在降低 5 年慢性肾脏病风险和减轻急性肾损伤负担方面优于 GLP-1RA，特别是在尚未出现既往肾病的患者中获益更佳。尽管 GLP-1RA 在死亡率等次要结局上略有优势，但该成果有力支持了 SGLT2i 作为 2 型糖尿病患者肾病一级预防的首选方案。

---

## 2. 关于 Hüser 等人发表的“药物中毒患者的重症监护管理”一文的读者来信。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41557001)
**期刊：** Intensive care medicine
**PMID：** 41557001
**DOI：** 10.1007/s00134-025-08279-0

### 第一部分 原文与翻译

**英文原标题：** Correspondence regarding the article by Hüser et al. on "Critical care management of the patient with pharmaceutical poisoning".

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

本文是针对 Hüser 等人关于药物中毒重症监护管理研究的一篇读者来信，体现了学术界对中毒急救管理方案的持续关注。此类文献通常通过同行评议式的互动，对原研究中的治疗细节、临床观察或方法论进行深入补充或探讨。虽然由于其信函性质缺乏详细摘要，但它在完善中毒患者重症监护临床路径及促进学术争鸣方面具有重要的参考价值。

---

## 3. 手术期间如何设置呼吸机？指导术中机械通气的关键原则。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41557000)
**期刊：** Intensive care medicine
**PMID：** 41557000
**DOI：** 10.1007/s00134-026-08301-z

### 第一部分 原文与翻译

**英文原标题：** How to set the ventilator during surgery? Key principles to guide intraoperative mechanical ventilation.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

本文旨在阐述手术期间机械通气设置的核心指导原则，为麻醉医师提供标准化的临床决策依据。文章重点聚焦于肺保护性通气策略的实施，探讨了如何通过优化呼吸机参数来降低术后肺部并发症的风险。作为该领域的权威指导性文献，其核心贡献在于将复杂的通气理论转化为可操作的术中管理准则，对于改善患者围术期预后具有高度的实践价值。

---

## 4. 从静脉-静脉体外膜肺氧合转为静脉-动脉或混合体外膜肺氧合：基于体外生命支持组织登记库的分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41556746)
**期刊：** Critical care medicine
**PMID：** 41556746
**DOI：** 10.1097/CCM.0000000000007027

### 第一部分 原文与翻译

**英文原标题：** Conversion From Venovenous to Venoarterial or Hybrid Extracorporeal Membrane Oxygenation: Analysis From the Extracorporeal Life Support Organization Registry.

> **英文摘要：**
> OBJECTIVES: Venovenous extracorporeal membrane oxygenation (ECMO) represents a standard and well-accepted modality of treating patients with refractory respiratory failure. Nevertheless, some patients might develop refractory hypoxemia, hemodynamic compromise or end-organ perfusion requiring a change. This study analyzed characteristics and outcomes of patients requiring a change from venovenous to a different ECMO configuration.
> 
> DESIGN: Multicenter, retrospective, observational analysis of the Extracorporeal Life Support Organization Registry (2010-2020) in adult patients (≥ 18 yr old) underwent venovenous ECMO as initial cannulation strategy.
> 
> SETTING AND PATIENTS: Comparison of patients who remained on venovenous ECMO vs. those who underwent configuration conversion and multivariable analysis to assess variables associated with configuration change.
> 
> INTERVENTIONS: None.
> 
> MEASUREMENTS AND MAIN RESULTS: Among 28,888 eligible venovenous ECMO runs, 702 (2.4%) received a change from the original configuration, including 399 (56.8%) conversions to venoarterial and 303 (43.2%) to hybrid ECMO configurations. Variables associated with conversion included: pre-ECMO cardiac conditions, bridge to lung transplant as indication, use of milrinone, epinephrine, sildenafil, bicarbonate, and 24-hour Pao2 value. Conversion occurred at a median of 56 hours (interquartile range, 11.5-210 hr) after ECMO initiation, with earlier conversion to hybrid configuration. Increased rates of cardiovascular, hemorrhagic, vascular, renal, metabolic, infective, and circuit-related complications were reported in converted patients. In-hospital mortality was higher in converted patients (60.8%) overall, and highest for venovenous to venoarterial patients (63.2%).
> 
> CONCLUSIONS: The venovenous patients converted to other ECMO configurations were 2.4% and experienced higher complication and mortality rates. Variables associated with conversion highlight the importance of initial configuration selection and should be considered as part of the risk stratification framework when evaluating a patient for individualized ECMO support mode/configuration.

> **中文摘要：**
> 目的：静脉-静脉体外膜肺氧合（VV ECMO）是治疗难治性呼吸衰竭的一种标准且被广泛接受的模式。然而，部分患者可能会出现难治性低氧血症、血流动力学受损或终末器官灌注不足，从而需要更改模式。本研究分析了需要从静脉-静脉转为不同ECMO配置的患者特征及预后。设计：对体外生命支持组织（ELSO）登记库（2010-2020年）中接受VV ECMO作为初始插管策略的成年患者（≥18岁）进行多中心、回顾性、观察性分析。设置与患者：比较维持VV ECMO的患者与接受配置转换的患者，并进行多因素分析以评估与配置更改相关的变量。干预措施：无。测量与主要结果：在28,888例符合条件的VV ECMO运行中，702例（2.4%）更改了原始配置，包括399例（56.8%）转为静脉-动脉（VA）配置，以及303例（43.2%）转为混合ECMO配置。与转换相关的变量包括：ECMO前心脏状况、以肺移植桥接为适应证、使用米力农、肾上腺素、西地那非、碳酸氢盐以及24小时PaO2值。转换发生在中位时间56小时（四分位间距：11.5-210小时），其中转为混合配置的时间更早。转换后的患者心血管、出血、血管、肾脏、代谢、感染及管路相关并发症的发生率升高。总的住院死亡率在转换患者中更高（60.8%），其中从VV转为VA的患者死亡率最高（63.2%）。结论：转为其他ECMO配置的VV患者占2.4%，且经历了更高的并发症发生率和死亡率。与转换相关的变量突显了初始配置选择的重要性，在评估患者个体化ECMO支持模式/配置时，应将其作为风险分层框架的一部分予以考虑。

### 第二部分 AI 大师评价

这项基于ELSO登记库的大规模回顾性研究，系统分析了成人VV ECMO在治疗过程中转换为VA或混合模式的发生率、预测因子及临床结局。研究指出，虽然模式转换的比例较低（2.4%），但一旦发生转换，患者的并发症发生率和住院死亡率显著升高。通过识别ECMO前的临床指标和早期生理参数作为转换预测因子，该研究强调了精准选择初始ECMO配置的必要性，为优化危重症患者的个体化体外生命支持方案提供了重要的循证依据。

---

## 5. 翻译标题未提供

**期刊：** 期刊信息缺失
**PMID：** PMID未提供

### 第一部分 原文与翻译

**英文原标题：** 原文标题未提供

> **英文摘要：**
> 原文摘要未提供

> **中文摘要：**
> 翻译摘要未提供

### 第二部分 AI 大师评价

AI评价未提供

---

## 6. 持续性发热性中性粒细胞减少症中重复血培养的诊断率及血流感染的风险因素

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41556483)
**期刊：** Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
**PMID：** 41556483
**DOI：** 10.1093/cid/ciag014

### 第一部分 原文与翻译

**英文原标题：** Diagnostic Yield of Repeat Blood Cultures and Risk Factors for Bloodstream Infection in Persistent Febrile Neutropenia.

> **英文摘要：**
> BACKGROUND: The optimal frequency of repeat blood cultures in persistent febrile neutropenia (FN) remains unknown. This study aims to identify opportunities for blood culture diagnostic stewardship in persistent FN.
> 
> METHODS: This is a retrospective cohort study of patients with hematology/oncology diagnoses and an FN episode >3 days. Generalized estimating equation logistic regression models were used to evaluate risk factors for new bloodstream infection (BSI) after FN day 3.
> 
> RESULTS: Among 620 patients, median FN duration was 5 days and median blood culture bottles collected per patient was 12. On FN day 1, 25% of patients had a positive blood culture; on FN days 2-9, <5% of patients per day had a new organism isolated. Among 31 new organisms isolated after FN day 3, 8 (26%) were contaminants. Of 503 patients with ≥1 blood culture collected after FN day 3, 19 (4%) had a new BSI after FN day 3. FN onset in the peri-hematopoietic cell transplant (HCT) period (day -7 to +30) was associated with lower odds of new BSI after FN day 3 (OR 0.18; 95%CI [0.04-0.71]; p=0.01).Thirty-six patients died within 30 days after FN day 3, including 4 with a new BSI after FN day 3; 1 death was attributable to BSI after FN day 3.
> 
> CONCLUSIONS: Detection of new BSI after FN day 3 was uncommon, demonstrating low diagnostic yield of repeat blood cultures after FN day 3. FN episodes in the peri-HCT period may be a potential focus for blood culture diagnostic stewardship initiatives.

> **中文摘要：**
> 背景：在持续性发热性中性粒细胞减少症（FN）中，重复血培养的最佳频率尚不明确。本研究旨在确定持续性 FN 中血培养诊断管理的机会。
> 
> 方法：这是一项针对血液/肿瘤诊断且 FN 发作持续时间 >3 天的患者进行的回顾性队列研究。采用广义估计方程逻辑回归模型评估 FN 第 3 天后发生新发血流感染（BSI）的风险因素。
> 
> 结果：在 620 名患者中，中位 FN 持续时间为 5 天，每名患者采集的血培养瓶中位数为 12 瓶。在 FN 第 1 天，25% 的患者血培养呈阳性；在 FN 第 2-9 天，每天新分离出微生物的患者比例 <5%。在 FN 第 3 天后分离出的 31 个新微生物中，有 8 个（26%）为污染菌。在 FN 第 3 天后采集了 ≥1 次血培养的 503 名患者中，19 名（4%）在 FN 第 3 天后出现了新发 BSI。围造血干细胞移植（HCT）期（第 -7 天至 +30 天）开始的 FN 与 FN 第 3 天后较低的新发 BSI 几率相关（OR 0.18；95%CI [0.04-0.71]；p=0.01）。36 名患者在 FN 第 3 天后的 30 天内死亡，其中 4 名在 FN 第 3 天后有新发 BSI；1 例死亡可归因于 FN 第 3 天后的 BSI。
> 
> 结论：FN 第 3 天后检测到新发 BSI 的情况并不常见，表明 FN 第 3 天后重复血培养的诊断率较低。围 HCT 期的 FN 发作可能是血培养诊断管理倡议的潜在重点。

### 第二部分 AI 大师评价

本研究通过对 620 名血液肿瘤患者的回顾性分析，评估了持续性发热性中性粒细胞减少症（FN）患者重复血培养的临床收益。研究发现，FN 第 3 天后新发血流感染的检出率极低且污染率较高，有力地证明了过度进行血培养采集的现状。该研究为临床实施诊断管理（Diagnostic Stewardship）提供了数据支持，提出围造血干细胞移植期是减少不必要培养的关键突破口，具有显著的资源优化指导意义。

---

## 7. 辅助基层到专科医疗转诊的大语言模型聊天机器人：一项随机对照试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41555035)
**期刊：** Nature medicine
**PMID：** 41555035
**DOI：** 10.1038/s41591-025-04176-7

### 第一部分 原文与翻译

**英文原标题：** An LLM chatbot to facilitate primary-to-specialist care transitions: a randomized controlled trial.

> **英文摘要：**
> Patient-facing large language models (LLMs) hold potential to streamline inefficient transitions from primary to specialist care. We developed the preassessment (PreA), an LLM chatbot co-designed with local stakeholders, to perform the general medical consultations for history-taking, preliminary diagnoses, and test ordering that would normally be performed by primary care providers and to generate referral reports for specialists. PreA was tested in a randomized controlled trial involving 111 specialists from 24 medical disciplines across two health centers, where 2,069 patients (1,141 women; 928 men) were randomly assigned to use PreA independently (PreA-only), use it with staff support (PreA-human), or not use it (No-PreA) before specialist consultation. The trial met its primary end points with the PreA-only group showing significantly reduced physician consultation duration (28.7% reduction; 3.14 ± 2.25 min) compared to the No-PreA group (4.41 ± 2.77 min; P < 0.001), alongside significant improvements in physician-perceived care coordination (mean scores 113.1% increase; 3.69 ± 0.90 versus 1.73 ± 0.95; P < 0.001) and patient-reported communication ease (mean scores 16.0% increase; 3.99 ± 0.62 versus 3.44 ± 0.97; P < 0.001). Equivalent outcomes between the PreA-only and PreA-human groups confirmed the autonomous operation capability. Co-designed PreA outperformed the same model with additional fine-tuning on local dialogues across clinical decision-making domains. Co-design with local stakeholders, compared to passive local data collecting, represents a more effective strategy for deploying LLMs to strengthen health systems and enhance patient-centered care in resource-limited settings. Chinese Clinical Trial Registry identifier: ChiCTR2400094159 .

> **中文摘要：**
> 面向患者的大语言模型（LLMs）具有优化基层医疗到专科医疗之间低效转诊过程的潜力。我们开发了名为“预评估（PreA）”的大语言模型聊天机器人，该工具与当地利益相关者共同设计，用于执行通常由基层医疗服务提供者完成的病史采集、初步诊断和检查开具工作，并为专科医生生成转诊报告。在两家医疗中心、涉及24个医学学科的111名专科医生的随机对照试验中，2,069名患者（1,141名女性；928名男性）在专科咨询前被随机分配到独立使用PreA组（PreA-only）、在工作人员支持下使用PreA组（PreA-human）或不使用PreA组（No-PreA）。试验达到了其主要终点，与No-PreA组（4.41 ± 2.77分钟；P < 0.001）相比，PreA-only组的医生咨询时间显著减少（缩短28.7%；3.14 ± 2.25分钟），同时医生感知的诊疗协调性（平均得分增加113.1%；3.69 ± 0.90对1.73 ± 0.95；P < 0.001）和患者报告的沟通便捷性（平均得分增加16.0%；3.99 ± 0.62对3.44 ± 0.97；P < 0.001）显著提高。PreA-only组与PreA-human组之间的等效结果证实了其自主运行能力。在临床决策领域，共同设计的PreA表现优于在本地对话数据上进行额外微调的相同模型。与被动收集本地数据相比，与当地利益相关者共同设计是将大语言模型部署于加强医疗卫生系统并在资源有限的环境中提升以患者为中心医疗服务的更有效策略。中国临床试验注册中心标识符：ChiCTR2400094159。

### 第二部分 AI 大师评价

本研究通过一项大规模随机对照试验验证了共同设计的大语言模型聊天机器人（PreA）在优化转诊流程中的显著效能。PreA不仅显著缩短了医生的咨询时间，还大幅提升了诊疗协调性和患者沟通体验，展示了在无人工干预下的高度自主性。研究强调，相较于单纯的数据微调，与利益相关者进行深度“共同设计”是LLM有效融入医疗系统并改善资源受限地区医疗质量的关键策略，为AI驱动的临床路径优化提供了强有力的实证支持。

---

## 8. 双倍剂量伏美替尼一线治疗携带EGFR L858R突变的局部晚期或转移性非小细胞肺癌患者：一项前瞻性、多中心、II期研究 (FIRM)

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41554745)
**期刊：** Nature communications
**PMID：** 41554745
**DOI：** 10.1038/s41467-026-68554-6

### 第一部分 原文与翻译

**英文原标题：** Double-dose firmonertinib as first-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer harboring EGFR L858R mutation: a prospective, multicenter, phase II study (FIRM).

> **英文摘要：**
> Progression-free survival (PFS) with first-line third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors remains suboptimal in EGFR L858R-mutated advanced non-small-cell lung cancer (NSCLC), highlighting a need for strategies to delay resistance. This single-arm, phase II study (FIRM; ChiCTR2200060897) evaluates first-line double-dose firmonertinib (160 mg/day) in adults with L858R-mutated locally advanced or metastatic NSCLC. With a median follow-up of 27.5 months in 33 patients, primary endpoint was a median PFS of 21.1 months. Secondary endpoints include an unreached median overall survival, an objective response rate of 75.8%, a disease control rate of 90.9%, and an 18-month PFS rate of 63.1%. Grade ≥3 treatment-emergent adverse events occur in 6.1% of patients. Baseline circulating tumor DNA (ctDNA) variant allele frequency predicts ctDNA clearance at cycle 3 day 1, which correlates with longer PFS. Double-dose firmonertinib shows promising efficacy and tolerability, supporting its preliminary potential as first-line treatment for EGFR L858R-mutated advanced NSCLC.

> **中文摘要：**
> 在携带EGFR L858R突变的晚期非小细胞肺癌（NSCLC）中，一线使用第三代表皮生长因子受体（EGFR）酪氨酸激酶抑制剂的无进展生存期（PFS）仍不理想，这凸显了对于延迟耐药发生策略的需求。这项单臂、II期研究（FIRM；ChiCTR2200060897）评估了双倍剂量伏美替尼（160 mg/天）一线治疗L858R突变的局部晚期或转移性NSCLC成年患者。在对33名患者进行中位随访27.5个月的研究中，主要终点中位PFS为21.1个月。次要终点包括：中位总生存期尚未达到，客观缓解率为75.8%，疾病控制率为90.9%，以及18个月PFS率为63.1%。6.1%的患者发生了≥3级的治疗期间不良事件。基线循环肿瘤DNA（ctDNA）变异等位基因频率可预测第3周期第1天的ctDNA清除情况，且该清除情况与更长的PFS相关。双倍剂量伏美替尼显示出令人鼓舞的疗效和耐受性，支持其作为EGFR L858R突变晚期NSCLC一线治疗的初步潜力。

### 第二部分 AI 大师评价

本研究（FIRM研究）针对EGFR L858R突变这一常规剂量三代TKI获益受限的临床难点，通过前瞻性II期试验验证了双倍剂量伏美替尼一线治疗的卓越疗效。结果显示其21.1个月的中位PFS远超历史常规剂量表现，且≥3级不良事件发生率极低（6.1%），实现了疗效增强与安全性控制的平衡。此外，研究引入ctDNA动力学作为早期预测指标，增强了结果的生物学解释深度。尽管为单臂研究，但其为L858R突变NSCLC的精准治疗提供了重要的高剂量强化治疗证据。

---

## 9. 非心脏、非肝移植手术中的术中连续肾替代治疗：一项观察性队列可行性研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41553965)
**期刊：** Blood purification
**PMID：** 41553965
**DOI：** 10.1159/000548879

### 第一部分 原文与翻译

**英文原标题：** Intraoperative continuous renal replacement therapy in non-cardiac, non-liver transplantation surgery: an observational cohort feasibility study.

> **英文摘要：**
> INTRODUCTION: Renal replacement therapy (RRT) is commonly used to manage metabolic disturbances in critically ill patients with acute kidney injury. While intraoperative RRT has been assessed in liver transplantation and cardiac surgery, its use in other surgical contexts remains unexplored. This study aimed to assess the feasibility of intraoperative continuous RRT (IoCRRT) in non-cardiac, non-liver transplant surgeries. Secondary objectives included evaluating safety and describing the patient population. METHODS: This retrospective study included all adult patients who underwent IoCRRT between January 2013 and January 2021 at Hospices Civils de Lyon (Lyon, France). Patients were classified as undergoing emergency or elective surgery. Data on IoCRRT indication, feasibility, safety, renal function at hospital discharge and mortality were analyzed. RESULTS: IoCRRT was successfully implemented in all 43 patients. Severe acidosis (pH < 7.2) was the main indication for IoCRRT in 27 patients (82%) of the emergency group, while IoCRRT was initiated to prevent metabolic complications and electrolyte imbalances in elective surgeries. Regional citrate anticoagulation was used in 36 (84%) cases. No adverse event was reported. At hospital discharge, no survivor progressed to end-stage renal disease; 4 (29%) patients exhibited a glomerular filtration rate (GFR) of 60-90 mL/min/1.73m², and 10 (71%) an GFR > 90 mL/min/1.73m². Twenty-seven patients (63%) died within 30 days. CONCLUSION: IoCRRT seems to be a feasible and safe adjunctive therapy during emergency or elective surgery in patients with severe metabolic disorders. No IoCRRT-related complication was reported. Renal function appeared preserved. Further prospective studies are warranted to confirm these findings.

> **中文摘要：**
> 引言：肾替代治疗（RRT）通常用于管理伴有急性肾损伤的危重患者的代谢紊乱。虽然术中RRT已在肝移植和心脏手术中得到评估，但在其他手术背景下的使用仍未得到探索。本研究旨在评估非心脏、非肝移植手术中术中连续RRT（IoCRRT）的可行性。次要目标包括评估安全性并描述患者群体。方法：这项回顾性研究纳入了2013年1月至2021年1月期间在里昂民用医院（法国里昂）接受IoCRRT的所有成年患者。患者被分为接受急诊手术或择期手术。分析了IoCRRT的指征、可行性、安全性、出院时的肾功能和死亡率数据。结果：IoCRRT在所有43名患者中成功实施。严重酸中毒（pH < 7.2）是急诊组27名患者（82%）实施IoCRRT的主要指征，而择期手术中启动IoCRRT则是为了预防代谢并发症和电解质失衡。36例（84%）使用了局部枸橼酸抗凝。未报告不良事件。出院时，无幸存者进展为终末期肾病；4名（29%）患者的肾小球滤过率（GFR）为60-90 mL/min/1.73m²，10名（71%）患者的GFR > 90 mL/min/1.73m²。27名患者（63%）在30天内死亡。结论：对于患有严重代谢障碍的患者，IoCRRT在急诊或择期手术中似乎是一种可行且安全的辅助疗法。未报告与IoCRRT相关的并发症。肾功能似乎得到了保留。仍需进一步的前瞻性研究来证实这些发现。

### 第二部分 AI 大师评价

本研究填补了术中连续肾替代治疗（IoCRRT）在非心脏及非肝移植手术领域的研究空白，通过对43例回顾性病例的分析，论证了该技术在急诊及择期高危手术中的可行性与安全性。研究发现IoCRRT能有效纠正严重酸中毒并预防代谢紊乱，且未观察到治疗相关的并发症，幸存者的肾功能保护效果良好。尽管研究人群的30天死亡率较高（63%），但这主要反映了该手术群体的极高危属性，而非IoCRRT本身的风险。总体而言，该研究为复杂手术中的术中代谢管理提供了重要的循证依据和新的生命支持思路。

---

## 10. 钠-葡萄糖协同转运蛋白2抑制剂在不同糖尿病状态和白蛋白尿水平下的疗效：一项荟萃分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41202026)
**期刊：** JAMA
**PMID：** 41202026
**DOI：** 10.1001/jama.2025.20835

### 第一部分 原文与翻译

**英文原标题：** Effects of Sodium Glucose Cotransporter 2 Inhibitors by Diabetes Status and Level of Albuminuria: A Meta-Analysis.

> **英文摘要：**
> IMPORTANCE: There is uncertainty about the effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors in participants with chronic kidney disease, with guidelines offering different strengths of recommendation based on diabetes status and urine albumin to creatinine ratio (UACR).
> 
> OBJECTIVE: To assess the relative and absolute effects of SGLT2 inhibitor use across efficacy and serious safety outcomes in participants stratified by diabetes status and UACR (≥200 mg/g or <200 mg/g).
> 
> DATA SOURCES AND STUDY SELECTION: Included 8 randomized clinical trials that studied an SGLT2 inhibitor with a label indication for use in kidney disease and recorded longitudinal kidney outcomes and baseline data on albuminuria.
> 
> DATA EXTRACTION AND SYNTHESIS: Data were combined using inverse variance-weighted meta-analysis; group-specific absolute effects were estimated by applying relevant relative risks to the event rates of the placebo groups.
> 
> MAIN OUTCOMES AND MEASURES: Assessed the effects of SGLT2 inhibitor use on clinical efficacy and safety outcomes. Heterogeneity by baseline level of UACR was assessed separately by diabetes status.
> 
> RESULTS: A total of 58 816 participants (mean age, 64 [SD, 10] years; 35% were female; 48 946 with diabetes and 9870 without diabetes) were included from trials comparing an SGLT2 inhibitor vs placebo. Allocation to an SGLT2 inhibitor produced a lower rate of kidney disease progression (33 vs 48 for placebo per 1000 patient-years; hazard ratio [HR], 0.65 [95% CI, 0.60-0.70] in those with diabetes and 32 vs 46 per 1000; HR, 0.74 [95% CI, 0.63-0.85] in those without diabetes), a lower rate of acute kidney injury (14 vs 18 per 1000 [HR, 0.77; 95% CI, 0.69-0.87] with diabetes and 13 vs 18 per 1000 [HR, 0.72; 95% CI, 0.56-0.92] without diabetes), a lower rate of any hospitalization (202 vs 231 per 1000 [HR, 0.90; 95% CI, 0.87-0.92] with diabetes and 203 vs 237 per 1000 [HR, 0.89; 95% CI, 0.83-0.95] without diabetes), and a lower rate of any death (42 vs 47 per 1000 [HR, 0.86; 95% CI, 0.80-0.91] with diabetes and 42 vs 48 per 1000 [HR, 0.91; 95% CI, 0.78-1.05] without diabetes). Diabetes-specific HRs were similar in participants (with a UACR ≥200 mg/g vs with a UACR <200 mg/g) considered separately. Higher absolute risk at a UACR of 200 mg/g or greater meant larger estimated absolute benefits on kidney disease progression were evident in this subgroup. Clear absolute benefits were evident for other efficacy outcomes, and particularly hospitalization, in participants with a UACR less than 200 mg/g. Net absolute benefits remained in the analyses of non-heart failure populations and when estimated glomerular filtration rate was less than 60 mL/min/1.73 m2.
> 
> CONCLUSIONS AND RELEVANCE: Within the studied participants, there were clear absolute benefits of SGLT2 inhibitors on kidney, hospitalization, and mortality outcomes irrespective of diabetes status and level of UACR.

> **中文摘要：**
> 【重要性】钠-葡萄糖协同转运蛋白 2 (SGLT2) 抑制剂在慢性肾脏病患者中的疗效仍存在不确定性，现有指南根据糖尿病状态和尿白蛋白/肌酐比值 (UACR) 提供了不同强度的推荐。【目的】评估 SGLT2 抑制剂在根据糖尿病状态和 UACR（≥200 mg/g 或 <200 mg/g）分层的受试者中，对疗效和严重安全性结局的相对及绝对影响。【数据来源与研究选择】纳入了 8 项随机临床试验，这些试验研究了具有肾脏疾病适应证标签的 SGLT2 抑制剂，并记录了纵向肾脏结局和白蛋白尿的基线数据。【数据提取与合成】使用逆方差加权荟萃分析法合并数据；通过将相关的相对风险应用于安慰剂组的事件发生率，估算特定组别的绝对效应。【主要结局与测量指标】评估了 SGLT2 抑制剂对临床疗效和安全性结局的影响。分别根据糖尿病状态评估了基线 UACR 水平产生的异质性。【结果】共纳入 58,816 名受试者（平均年龄 64 岁；35% 为女性；48,946 名患有糖尿病，9,870 名未患糖尿病），这些受试者来自比较 SGLT2 抑制剂与安慰剂的试验。分配至 SGLT2 抑制剂组的患者肾脏疾病进展率较低（糖尿病组：HR 0.65 [95% CI, 0.60-0.70]；非糖尿病组：HR 0.74 [95% CI, 0.63-0.85]），急性肾损伤发生率较低（糖尿病组：HR 0.77；非糖尿病组：HR 0.72），任何住院率较低（糖尿病组：HR 0.90；非糖尿病组：HR 0.89），以及全因死亡率较低（糖尿病组：HR 0.86；非糖尿病组：HR 0.91）。在分别考虑时，糖尿病特异性 HR 在 UACR ≥200 mg/g 与 UACR <200 mg/g 的受试者中相似。由于 UACR ≥200 mg/g 的患者基线绝对风险更高，该亚组在肾脏疾病进展方面的估计绝对获益更显著。对于 UACR <200 mg/g 的受试者，其他疗效结局（尤其是住院）也显示出明显的绝对获益。在非心力衰竭人群以及估算肾小球滤过率小于 60 mL/min/1.73 m² 的分析中，净绝对获益依然存在。【结论与相关性】在研究受试者中，无论糖尿病状态和 UACR 水平如何，SGLT2 抑制剂在肾脏、住院和死亡结局方面均具有显著的绝对获益。

### 第二部分 AI 大师评价

本项荟萃分析通过整合 8 项大型随机临床试验数据，系统证实了 SGLT2 抑制剂在不同糖尿病状态及白蛋白尿（UACR）水平下的临床获益。研究明确指出，无论患者是否合并糖尿病或尿蛋白水平高低，SGLT2 抑制剂均能显著降低肾病进展、急性肾损伤及住院风险。尽管高蛋白尿人群在肾脏保护方面的绝对获益更显著，但在低蛋白尿人群中，住院风险的降低同样提供了明确的临床价值。该研究为拓宽 SGLT2 抑制剂在慢性肾脏病管理中的应用范围提供了强有力的循证医学证据，有助于优化并统一相关临床指南。

---

速递结束，祝您工作愉快！